XOMA's CEO Presents At The Eighth Annual Lazard Capital Markets Healthcare Conference - Conference Call Transcript

XOMA Ltd. (XOMA)

Lazard Capital Markets Healthcare Conference 2011

November 15, 2011 1 AM ET

Executives

John Varian – Interim CEO

Paul Rubin – VP, Clinical Development and Chief Medical Officer

Presentation

Operator

[Starts Abruptly] introduce John Varian, who will be presenting to us today about his company XOMA.

John Varian

Compare to:
Previous Statements by XOMA
» XOMA's CEO Discusses Q3 2011 Results - Earnings Call Transcript
» XOMA CEO Discusses Q2 2011 Results - Earnings Call Transcript
» XOMA's CEO Discusses Q1 2011 Results - Earnings Call Transcript
» XOMA CEO Discusses Q4 2010 Results - Earnings Call Transcript

Thanks Colleen, and thank you to Lazard for having us present here giving us the opportunity to talk about XOMA and some of the new changes that are going on there. I joined the company at the end of August as the interim CEO. I've been involved with XOMA for the last nearly almost 3 years as a board member, and during those 3 years our focus has been on really one thing. XOMA is a company that over the years has had terrific science but there is a belief among the board and I think many others that XOMA has not really benefited as much from its own discoveries as it should have and so our focus has been on changing that making sure we are in a position to benefit from our own discoveries.

We’ll be making forward-looking statements of course today. So if you look at the assets that we have at XOMA the primary asset the thing that most people are focused on is XOMA 052 and it has just received its official name which is gevokizumab. So gevokizumab, it will be 052 we’ll be saying it that way today. Gevokizumab targets IL-1 beta, which is a validated anti-inflammatory target. We will be talking primarily today about an announcement which we made last week, which is a combination of really two things that we are implementing to build more value around gevokizumab.

1 2 3 Next › Last »